Skip to main menu
Skip to main content
Skip to footer
Accessibility Menu
Healthcare Professionals
About Us
Our Team
Leadership Team
Medical Advisory Board
Careers
Contact Us
Our Product
Science & Technology
Publications
Clinical
Patients
News
Healthcare Professionals
NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)
Home
»
NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)
View PDF Version
Other Posts
Next >>
⇧
Neurotech Pharmaceuticals, Inc. is now part of Alcon